Як цитувати
Анотація
Non-alcoholic fatty liver disease (NAFLD) is a scourge of the planet’s population, especially the developed countries. NAFLD development is due to the global increase in the number of overweight and obese people. NAFLD in its turn is the main factor of cardiovascular risk development. Early detection of the cardiovascular risk development with underlying NAFLD and overweight remains understudied. This article reviews the literature dealing with the diagnosis and treatment of NAFLD in overweight subjects.
Key words: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hypertension, endothelial lipase, lipid metabolism, overweight.
СУЧАСНІ ТЕНДЕНЦІЇ ДІАГНОСТИКИ ТА ЛІКУВАННЯ НЕАЛКОГОЛЬНИЙ ЖИРОВОЇ ХВОРОБИ ПЕЧІНКИ У ОСІБ З НАДЛИШКОВОЮ МАСОЮ ТІЛА
Бабак О.Я., Башкірова А.Д.
Неалкогольна жирова хвороба печінки (НАЖХП) - бич населення планети, особливо розвинених країн світу. Розвиток НАЖХП обумовлено глобальним зростанням кількості людей з надмірною масою тіла та ожирінням. У свою чергу НАЖБП є головним фактором розвитку кардіоваскулярного ризику. Рання діагностика розвитку кардіоваскулярного ризику на тлі НАЖХП і надлишкової маси тіла до кінця не вивчена. У даній статті представлений огляд літературних джерел по темі діагностики НАЖХП на тлі надлишкової маси тіла.
Ключові слова: неалкогольна жирова хвороба печінки, неалкогольний стеатогепатит, гіпертонічна хвороба, ендотеліальна ліпаза, ліпідний обмін, надлишкова маса тіла .
СОВРЕМЕННЫЕ ТЕНДЕНЦИИ ДИАГНОСТИКИ И ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ (НАЖБП) У ЛИЦ С ИЗБЫТОЧНОЙ МАССОЙ ТЕЛА
Бабак О.Я., Башкирова А.Д.
Неалкогольная жировая болезнь печени (НАЖБП) – бич населения планеты, в особенности развитых стран мира. Развитие НАЖБП обусловлено глобальным ростом количества людей с избыточной массой тела и ожирением. В свою очередь НАЖБП является главным фактором развития кардиоваскулярного риска. Ранняя диагностика развития кардиоваскулярного риска на фоне НАЖБП и избыточной массы тела до конца не изучена. В данной статье представлен обзор литературных источников по теме диагностики НАЖБП на фоне избыточной массы тела.
Ключевые слова: неалкогольная жировая болезнь печени, неалкогольный стеатогепатит , липидный обмен, избыточная масса тела.
Посилання
Review Team., LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG,…LeMair A. (2014). World Gastroenterology Organisation.. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 48(6):467-73. doi: 10.1097/MCG.0000000000000116. PubMed PMID: 24921212.
Torres DM, Harrison SA. (2012). Hepatic progenitor cells: Another piece in the nonalcoholic fatty liver disease puzzle. Hepatology. 56(6):2013-5. doi: 10.1002/hep.25903. PubMed PMID: 22729849.
Butrova L.I. (2014). Lekarstvennyie povrezhdeniya pecheniu patsientov s metabolicheskim sindromomi nealkogolnoy zhirovoy boleznyu pecheni:novyie vozmozhnosti profilaktiki i lecheniya [Medicinal liver damage in patients with metabolic sindromomi non-alcoholic fatty liver disease, new possibilities for prevention and treatment]. Meditsinskie novosti. 8(239):41-47.
Matthiessen J., Velsing Groth, S. Fagt et al. (2008). Prevalence and trends in overweight and obesity among children and adolescents in Denmark. Scand J Public Health. (36):153-160.
Lazebnik L.B. (2007). Vozrastnyie izmeneniya pecheni. Klinicheskie i morfologicheskie aspektyi. Klinicheskaya gerontologiya. 1:3-8.
Paltsev A.I. (2007). Metabolicheskiy sindrom. Vestnik assotsiatsii zasluzhennyih vrachey RF. (2):8-11.
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. (2005). Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 42(1):44-52. PubMed PMID: 15895401.
Machado M, Marques-Vidal P, Cortez-Pinto H. (2006). Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 45(4):600-6. Epub 2006 Jul 25. PubMed PMID: 16899321.
Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y,…Okanoue T. (2011). Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 9(5):428-33; doi: 10.1016/j.cgh.2011.01.023. PubMed PMID: 21320639.
Barritt AS 4th, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L,…Sanyal A. (2017) Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemp Clin Trials. 61:33-38. doi: 10.1016/j.cct.2017.07.015. PubMed PMID: 28735109.
Roytberg G. E. Metabolicheskiy sindrom. (2007) MED-press. Inform: 224.
Ivashkin V.T. Klinicheskie variantyi metabolicheskogo sindroma (2011). M.: Med. inform. Agentstvo: 220.
Marino L, Jornayvaz FR. (2015). Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol. 21(39):11053-76. doi:10.3748/wjg.v21.i39.11053. PubMed Central PMCID: PMC4607905.
Adolph TE, Grander C, Grabherr F, Tilg H. (2017). Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int J Mol Sci. 29;18(8). doi: 10.3390/ijms18081649. PubMed Central PMCID: PMC5578039.
P.V. Selivestrov, V.G. Radchenko. (2014). Optimizatsiya terapii bolnyih nealkogolnoy zhirovoy boleznyu pecheni. RZhGGK, (4):39-44.
Cusi K. (2009). Role of insulin resistanse and lipotoxy in non-alcoholic steatohepatitis. Clin Liver Dis.13 (4):545-63.
Shulpekova Yu.O. (2012). Patogeneticheskoe znachenie lipidov pri NAZhBP. RZhGGK. (1): 45-56.
Melnichenko G.A. (2012). Rasprostranennost NAZhBP pri ozhirenii i ee vzaimosvyaz s faktorami riska SSZ i SD 2-go tipa. RZhGGK (2): 45-52.
Ivashkin V.T., Maevskaya M.V. (2010). Lipotoksichnost i metabolicheskie narusheniya pri ozhirenii. RZhGGK, (1), 4-13.
Popova I.R. (2012). Rasprostranennost zabolevaniy organov pischevareniya u patsientov s izbyitochnoy massoy tela i ozhireniem. RZhGGK (5): 24-29.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, … Lisheng L. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 364(9438):937-52. PubMed PMID: 15364185.
Pavlov Ch.S. (2007). Printsipyi diagnostiki i podhodyi k terapii fibroza i tsiroza pecheni. Rus med zhurnal (1): 6-11.
Alempijevic T., Krstic M., Jesic R. (2009). Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. Word J Gastroenterol. 15(5):591-4.
Sheptulina A.F., Shirokova E.N., Ivashkin V.T. (2015). Neinvazivnaya diagnostika fibroza pecheni: rol syivorotochnyih markerov. RZhGGK (2): 28-40.
Hayashi T, Saitoh S, Fukuzawa K, Tsuji Y, Takahashi J, Kawamura Y, …Kumada H. (2017). Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver. 11(5):674-683. doi: 10.5009/gnl16440. PubMed Central PMCID: PMC5593330.
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. (2016). J Hepatol, http://dx.doi.org/10.1016/j.jhep.2015.11.004
Oparin A.A., Oparin A.G., Korenovskiy I.P., Lavrova N.V. (2012). Algoritmyi i kriterii UZI-diagnostiki v klinike vnutrennih bolezney: ucheb. posob. Harkov: Fakt: 80.
Mottin C.C., Moretto M., Padoin A.V. et al. (2004). The role of ultrasound in the diagnosis ofhepatic steatosis in morbidly obese patients. Obes Surg. 14: 635-637.
Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al. (2014). Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 40:1209–1222.
McPherson S., Stewart S.F., Henderson E. Et al. (2010). Simple non-invasive fibrosis scoring system can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 59(9):1265-9.
Dixon J.B., Bhathal P.S., O’Brien P.E. (2001). Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 21:91-100.
Ratziu V., Massard J., Charlotte F. et al. (2006). Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 6:6.
Schiavon L., Narciso-Schiavon J., de Carvalho-Filho R.J. (2014). Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. Word J Gastroenterol. 20(11):2854-66.
Schiavon L., Narciso-Schiavon J., de Carvalho-Filho R.J. (2014). Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. Word J Gastroenterol. 20(11):2854-66.
Lurie, Y., Webb, M., Cytter-Kuint, R., Shteingart, S., & Lederkremer, G. Z. (2015). Non-invasive diagnosis of liver fibrosis and cirrhosis. World Journal of Gastroenterology. 21(41):11567–11583. http://doi.org/10.3748/wjg.v21.i41.11567
Lin Z.H., Xin Y.N., Dong Q.J. et al. (2011). Performance of the aspartate aminotransferase-to-platelet ratio indexfor the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 53:726-36.
Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., …, Liddle C. (2002). NASH and insulin re-sistance: Insulin hypersecretion and specific association with the insulin re-sistance syndrome. Hepatology. 35: 373-379.
Shimada M., Kawahara H., Ozaki K., Fukura M., Yano H., Tsuchishima M., …, Takase S.. (2007). Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol. 102: 1931-1938.
Poynard T., Ratziu V., Charlotte F., Messous D., Munteanu M. F., Imbert-Bismut,… Thabut. D. (2006). Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 6: 34.
Mantovani A. (2017). Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis. J Clin Transl Hepatol. 28;5(2):134-141. doi: 10.14218/JCTH.2017.00005. PubMed Central PMCID: PMC5472934.
Miele L., Forgione A., La Torre G., Vero V., Cefalo C., …, Rapaccini G.L. (2009). Serum levels of hyalu-ronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res. 154: 194-201.
Kleiner D.E., Brunt E.M., van Natta M., Behling C., Contos M.J., …, Unalp-Arida. (2005). De-sign and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41: 1313-1321.
Salkic NN, Jovanovic P, Hauser G, Brcic M. (2014). FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol. 109(6):796-809. doi: 10.1038/ajg.2014.21. Epub 2014 Feb18. Review. PubMed PMID: 24535095.
Pavlov Ch.S. (2008). Sovremennyie vozmozhnosti elastometrii, fibro- i aktitesta v diagnostike fibroza pecheni. Ros. zhurn. Gastroenterologii, gepatologii, koloproktologii. 18(4): 43-52.
Dam-Larsen S., Becker U., Franzmann M.B., Larsen K., Christoffersen P., Bendtsen F. (2009). Final results of a long-term, clinical follow-up in fatty liver patients. Scandinavian Journal of Gastroenterology. 44(10): 1236-1243.
Bergqvist, C.-J., Skoien, R., Horsfall, L., Clouston, A. D., Jonsson, J. R. and Powell, E. E. (2013), Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern Med J, 43: 247–253. doi:10.1111/j.1445-5994.2012.02848.x
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M. and Sanyal, A. J. (2012), The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55: 2005–2023. doi:10.1002/hep.25762
Schekina M.I. (2013). Metabolicheskiy sindrom - pandemiya XXI veka. Chem myi mozhem pomoch patsientu. Meditsinskiy sovet. V. 5(2):38-45.
Tolman, K. G., & Dalpiaz, A. S. (2007). Treatment of non-alcoholic fatty liver disease. Therapeutics and Clinical Risk Management, 3(6), 1153–1163.
Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifesyill intervention or metformin. N Engl J Med. V.346:393-403.
Standards of Medical Care in Diabetes 2012. Diabetes Care. V.35(Suppl. 1):11–63.
Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, …, Spénard J. (2011). A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 54(5):1011-9. doi: 10.1016/j.jhep.2010.08.030. Epub 2010 Oct 31. PubMed PMID:21145828.
Lavine, J. E., Schwimmer, J. B., Van Natta, M. L., Molleston, J. P., Murray, K. F., Rosenthal, P., … Robuck, P. R. (2011). Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial. JAMA : The Journal of the American Medical Association, 305(16), 1659–1668. http://doi.org/10.1001/jama.2011.520
Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. (2007). Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 47(1):135-41.Epub 2007 Mar 8. PubMed PMID: 17400325.
Argo CK, Loria P, Caldwell SH, Lonardo A. (2008). Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 48(2):662-9. doi:10.1002/hep.22402. Review. PubMed PMID: 18666246.
Drapkina O. M., Smirin V.I., Ivashkin V.T. Patogenez, lechenie i epidemiologiya NAZhBP — chto novogo? Epidemiologiya NAZhBP v Rossii. Russkiy meditsinskiy zhurnal. #28:1717-1721.
Ivashkin K.V., Bueverov A.O. (2011). Adiponektin - vazhneyshee zveno patogeneza i mishen terapevticheskogo vozdeystviya pri nealkogolnoy zhirovoy bolezni pecheni. Klinicheskie perspektivyi gastroenterologii, gepatologii. #5:3-13.
Samson SL, Bajaj M. (2013). Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications. 27(4):401-6. doi:10.1016/j.jdiacomp.2012.12.005. Epub 2013 Jan 24. Review. PubMed PMID: 23352496.
Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. (2007). Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 22(5):634-8. PubMed PMID: 17444848.
Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico SD, …, Cuccurullo F. (2002). Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol. 64(11):1661-7. PubMed PMID: 12429355.
Zvenigorodskaya L.A. (2015). Nealkogolnaya zhirovaya bolezn pecheni: evolyutsiya predstavleniy, patogeneticheskie aktsentyi, podhodyi k terapii. Trudnyiy patsient #10:11
Matveev A.V. (2013). Gepatoprotektoryi. Analiz mezhdunarodnyih issledovaniy po preparatam gruppyi lekarstv dlya pecheni. Simferopol:384.
Entsiklopediya lekarstv i tovarov aptechnogo assortimenta [Elektronnyiy resurs] URL: http://www.rlsnet.ru.
Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, …, Nevens F. (2011). Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):523-37; quiz 537. doi: 10.1586/egh.11.47. Review. PubMed PMID: 21780899.
"Inter Collegas" є журналом відкритого доступу: всі статті публікуються у відкритому доступі без періоду ембарго, на умовах ліцензії Creative Commons Attribution ‒ Noncommercial ‒ Share Alike (CC BY-NC-SA, з зазначенням авторства ‒ некомерційна ‒ зі збереженням умов); контент доступний всім читачам без реєстрації з моменту його публікації. Електронні копії архіву журналів розміщені у репозиторіях ХНМУ та Національної бібліотеки ім. В.І. Вернадського.